Business Context and Reporting Period
Company: 60 Degrees Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 30, 2026
Event: Entry into a Material Definitive Agreement for a private placement offering. The closing of the transaction occurred on July 31, 2026.
Key Financial Metrics
Capital Raised: Approximately $1.0 million in gross proceeds (before placement agent fees and offering expenses).
Securities Issued:
- 191,571 shares of Common Stock at $1.74 per share.
- 383,142 Pre-funded Warrants at $1.739 per warrant.
- 574,413 Series A Warrants and 574,413 Series B Warrants (Common Warrants).
Placement Agent Fees: 7.5% cash fee, 1.0% management fee, plus $50,000 in reimbursable expenses and warrants to purchase 43,103 shares.
Material Changes
This filing represents a discrete capital raise event rather than a periodic financial performance report. Consequently, there are no comparative revenue, profit, or cash flow metrics provided in this document. The primary material change is the increase in outstanding equity and warrant obligations resulting from the private placement.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize the proceeds to fund working capital, general operations, and its R&D program.
Warrant Terms:
- Common Warrants: Exercise price of $1.49 per share; exercisable immediately.
- Pre-funded Warrants: Exercise price of $0.001 per share; exercisable immediately.
- Expiration: Series A Warrants expire 5 years from the Effective Date of the registration statement; Series B Warrants expire 24 months from the Effective Date.
- Beneficial Ownership Limitation: Holders cannot exercise warrants if it would result in beneficial ownership exceeding 4.99% (or 9.99% at election) of outstanding shares, unless notice is provided.
- Registration Rights: The Company must file a registration statement for resale of shares within 45 days of July 30, 2026 (or 75 days if a full SEC review is required).
- Unregistered Securities: The offering was conducted under Section 4(a)(2) and Rule 506(b) exemptions.
Investor Verification Checklist
- Verify the actual net proceeds received after deducting the 8.5% total placement agent fees and $50,000 in expenses.
- Confirm the dilution impact of the 1,148,826 total warrants issued (Series A, Series B, and Pre-funded) relative to the current share count.
- Monitor the filing of the required registration statement to ensure it is declared effective within the 45-day deadline.
- Review the specific terms of the "Beneficial Ownership Limitation" to understand potential restrictions on future warrant exercises.
- Check for any subsequent filings regarding the status of the Company's research and development programs funded by this capital.